There are currently 103 clinical trials in Winter Park, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Shafran Gastroenterology Center, Conquest Research, AdventHealth Winter Park and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Charter Research, Winter Park, Florida
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Register for Updates
DIAMOND AF Post-Approval Study
NCT05230524
Recruiting
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: Florida Electrophysiology LLC, Winter Park, Florida
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
NCT04572243
Recruiting
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Gender:
All
Ages:
2 years and above
Trial Updated:
01/18/2024
Locations: Pediatric Neurology, P.A., Winter Park, Florida
Conditions: Epilepsies, Myoclonic
Register for Updates
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criter... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/03/2024
Locations: Charter Research - Winter Park ( Site 0012), Winter Park, Florida
Conditions: Alzheimer Disease
Register for Updates
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
NCT05011305
Recruiting
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US004, Winter Park, Florida
Conditions: Nonalcoholic Steatohepatitis, Fibrosis
Register for Updates
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
All
Ages:
50 years and above
Trial Updated:
12/11/2023
Locations: Charter Research, Winter Park, Florida
Conditions: Alzheimer Disease
Register for Updates
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
NCT05425446
Recruiting
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/26/2023
Locations: Clinical Site Partners - Orlando, Winter Park, Florida
Conditions: Celiac Disease
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Clinical Site Partners LLC dba CSP Orlando, Winter Park, Florida +1 locations
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
NCT05586958
Recruiting
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
08/24/2023
Locations: Conquest Research, LLC, Winter Park, Florida
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
Recruiting
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: AdventHealth Winter Park, Winter Park, Florida
Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2023
Locations: AdventHealth Winter Park, Winter Park, Florida
Conditions: Multiple Myeloma
Register for Updates
Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care
NCT05046158
Recruiting
Phase IV, randomized, prospective, multi-center, open-label, comparison of transforming powder dressing to standard of care dressing for healing diabetic foot ulcers.
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
06/27/2023
Locations: AdventHealth Medical Group Foot & Ankle at Winter Park, Winter Park, Florida
Conditions: Diabetic Foot Ulcer
Register for Updates